Associated Papers
ERBB family fusions are recurrent and actionable oncogenic targets across cancer types.
Schubert L et al.
Frontiers in Oncology, 2023
37168365 (PubMed )
Supplement: Table_4.xlsx › ERBB2_mutations
Molecular Signature Expands the Landscape of Driver Negative Thyroid Cancers.
Bim LV et al.
Cancers, 2021
34680332 (PubMed )
Supplement: cancers-13-05184-s001.zip › cancers-1388243_supplementary-for_xml › Supplementary_Table_S2.xlsx › variants
Select a paper to view details